Data-driven simulation of Fisher-Kolmogorov tumor growth models using Dynamic Mode Decomposition

TL;DR

This paper introduces a data-driven approach using Dynamic Mode Decomposition to significantly accelerate Fisher-Kolmogorov tumor growth simulations, enabling more efficient personalized cancer modeling with high accuracy.

Contribution

The study demonstrates that DMD can effectively reduce computational costs of tumor growth models while maintaining high prediction accuracy, advancing personalized oncology simulations.

Findings

Short-term prediction errors under 1%

Long-term errors under 20%

Effective over clinically-relevant parameter space

Abstract

The computer simulation of organ-scale biomechanistic models of cancer personalized via routinely collected clinical and imaging data enables to obtain patient-specific predictions of tumor growth and treatment response over the anatomy of the patient's affected organ. These patient-specific computational forecasts have been regarded as a promising approach to personalize the clinical management of cancer and derive optimal treatment plans for individual patients, which constitute timely and critical needs in clinical oncology. However, the computer simulation of the underlying spatiotemporal models can entail a prohibitive computational cost, which constitutes a barrier to the successful development of clinically-actionable computational technologies for personalized tumor forecasting. To address this issue, here we propose to utilize Dynamic-Mode Decomposition (DMD) to construct a low-dimensional representation of cancer models and accelerate their simulation. DMD is an unsupervised machine learning method based on the singular value decomposition that has proven useful in many applications as both a predictive and a diagnostic tool. We show that DMD may be applied to Fisher-Kolmogorov models, which constitute an established formulation to represent untreated solid tumor growth that can further accommodate other relevant cancer phenomena. Our results show that a DMD implementation of this model over a clinically-relevant parameter space can yield impressive predictions, with short to medium-term errors remaining under 1% and long-term errors remaining under 20%, despite very short training periods. We posit that this data-driven approach has the potential to greatly reduce the computational overhead of personalized simulations of cancer models, thereby facilitating tumor forecasting, parameter identification, uncertainty quantification, and treatment optimization.